CVS Health Corp Stock (CVS) Moved Up by 3.42% on Apr 28: A Full Analysis

Source Tradingkey

CVS Health Corp (CVS) moved up by 3.42%. The Healthcare Services & Equipment sector is down by 0.09%. The company outperformed the industry. Top 3 stocks by turnover in the sector: Unitedhealth Group Inc (UNH) up 3.85%; Boston Scientific Corp (BSX) down 2.77%; Centene Corp (CNC) up 14.19%.

SummaryOverview

What is driving CVS Health Corp (CVS)’s stock price up today?

CVS Health Corporation experienced an upward movement in its stock price, accompanied by significant intraday volatility. This performance appears to be largely driven by a combination of a strengthened earnings outlook, favorable regulatory developments, and positive analyst sentiment.

The company's reaffirmation of its full-year 2026 adjusted earnings per share guidance, along with an updated operating cash flow outlook, has instilled renewed confidence in its medium-term financial prospects. This follows a period of strong performance, including exceeding initial 2025 guidance.

Another key factor contributing to the positive sentiment is the more favorable-than-expected payment rate update for Medicare Advantage plans in 2027 by the Centers for Medicare & Medicaid Services. This development is seen as a significant tailwind for CVS's Aetna unit, supporting its earnings backdrop.

Furthermore, the proposed settlement with the Federal Trade Commission regarding insulin pricing has removed a notable regulatory overhang that had previously affected the company's Pharmacy Benefit Manager business. This resolution has reduced uncertainty and improved the profitability outlook for this segment.

Analyst forecasts also reflect this optimistic view, with a consensus "Buy" rating and several firms recently raising their price targets for CVS Health. Investors are also looking ahead to the company's upcoming first-quarter 2026 earnings report, which is anticipated to be released in early May, further contributing to market activity and the observed intraday movements.

Technical Analysis of CVS Health Corp (CVS)

Technically, CVS Health Corp (CVS) shows a MACD (12,26,9) value of [0.55], indicating a buy signal. The RSI at 56.72 suggests neutral condition and the Williams %R at -26.34 suggests oversold condition. Please monitor closely.

Fundamental Analysis of CVS Health Corp (CVS)

CVS Health Corp (CVS) is in the Healthcare Services & Equipment industry. Its latest annual revenue is $402.07B, ranking 2 in the industry. The net profit is $1.77B, ranking 5 in the industry. Company Profile

FundamentalAnalysis

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $93.86, a high of $105.00, and a low of $79.00.

More details about CVS Health Corp (CVS)

Company Specific Risks:

  • CVS Health faces significant financial and operational headwinds stemming from the underperformance of its Oak Street Health acquisition, which led to a nearly $6 billion goodwill impairment charge in Q3 2025 and subsequent plans to close underperforming clinics. Additionally, the company lowered its 2026 cash flow from operations guidance to at least $9 billion.
  • The company's Pharmacy Benefit Manager (PBM) segment, CVS Caremark, is under intensified regulatory scrutiny, including a federal audit identifying over $479 million in alleged overcharges between 2018 and 2021, and proposed state-level legislation that could prohibit pharmacies from operating PBMs, threatening CVS's integrated business model and potentially leading to store closures.
  • CVS is anticipating a decline of up to 10% in Aetna's Medicare Advantage membership for 2025 due to rising medical costs, which presents a significant near-term financial headwind despite some positive outlook for 2027 rates.
  • CVS subsidiaries are facing an ongoing legal overhang from a proposed class-action lawsuit filed on March 18, 2026, alleging improper handling of drug-manufacturer payments related to formulary placement.
Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Fed FOMC Meeting Is Approaching: Where Is the Focus? Will There Be More Rate Cuts This Year?Global financial markets are set for a "Super Central Bank Week" this week, as five major central banks, including the Federal Reserve, the European Central Bank, and the Bank of Japan, a
Author  TradingKey
13 hours ago
Global financial markets are set for a "Super Central Bank Week" this week, as five major central banks, including the Federal Reserve, the European Central Bank, and the Bank of Japan, a
placeholder
Japanese Yen extends the range play against USD; looks to BoJ for fresh impetusThe USD/JPY pair is seen consolidating in a narrow band around mid-159.00s during the Asian session on Tuesday as traders opt to wait for the crucial Bank of Japan (BoJ) before placing fresh directional bets.
Author  FXStreet
18 hours ago
The USD/JPY pair is seen consolidating in a narrow band around mid-159.00s during the Asian session on Tuesday as traders opt to wait for the crucial Bank of Japan (BoJ) before placing fresh directional bets.
placeholder
Bitcoin Returns to $79,000 Level. Prediction Markets Bullish on Breaking $80,000 in AprilBitcoin prices have strengthened again, breaking through $79,000 amid strong bullish sentiment; however, investors should be wary of this week's Federal Reserve interest rate decision.On
Author  TradingKey
Yesterday 10: 35
Bitcoin prices have strengthened again, breaking through $79,000 amid strong bullish sentiment; however, investors should be wary of this week's Federal Reserve interest rate decision.On
placeholder
WTI sticks to modest gains above $94.00 as Hormuz standoff fuels supply concernsWest Texas Intermediate (WTI) – the benchmark US Crude Oil price – kicks off the new week on a positive note and reverses a part of Friday's modest decline, though the upside remains capped.
Author  FXStreet
Yesterday 01: 12
West Texas Intermediate (WTI) – the benchmark US Crude Oil price – kicks off the new week on a positive note and reverses a part of Friday's modest decline, though the upside remains capped.
placeholder
Semiconductor Sector Continues to Rise, Should Retail Investors Buy Intel or AMD? On April 23, Eastern Time, Intel (INTC) reported its latest quarterly earnings results, showing that revenue grew 7% to $13.6 billion and earnings per share was $0.29, beating expectation
Author  TradingKey
Apr 24, Fri
On April 23, Eastern Time, Intel (INTC) reported its latest quarterly earnings results, showing that revenue grew 7% to $13.6 billion and earnings per share was $0.29, beating expectation
goTop
quote